EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 1st, 2022 • Cronos Group Inc. • Medicinal chemicals & botanical products
WHEREAS the Executive is currently employed by Hortican, another wholly-owned subsidiary of Cronos Group, in the position of Vice President, Operations pursuant to an offer of employment letter dated August 3, 2021 (the “Original Agreement”);
EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”)Option Award Agreement • August 6th, 2021 • Cronos Group Inc. • Medicinal chemicals & botanical products • Delaware
WHEREAS the Company wishes to engage the services of the Executive in the position of Chief Financial Officer of Cronos Group;
INVESTOR RIGHTS AGREEMENT by and between CRONOS GROUP INC. and ALTRIA GROUP, INC. Dated as of March 8, 2019Investor Rights Agreement • March 15th, 2019 • Cronos Group Inc. • Medicinal chemicals & botanical products
This INVESTOR RIGHTS AGREEMENT, dated as of March 8, 2019 (this “Agreement”), is entered into by and between Cronos Group Inc., a corporation organized under the Laws of the Province of Ontario (the “Company”), and Altria Group, Inc. a corporation organized under the Laws of the Commonwealth of Virginia (“Altria” and, together with the Company, the “Parties” and each, a “Party”).
SUBSCRIPTION AGREEMENT by and among CRONOS GROUP INC., ALTRIA SUMMIT LLC and, solely for the purposes specified herein, ALTRIA GROUP, INC. Dated as of December 7, 2018Subscription Agreement • December 10th, 2018 • Cronos Group Inc. • Medicinal chemicals & botanical products
This SUBSCRIPTION AGREEMENT, dated as of December 7, 2018 (this “Agreement”), is entered into by and among Cronos Group Inc., a corporation organized and existing under the Laws of the Province of Ontario (the “Company”), Altria Summit LLC, a limited liability company organized and existing under the Laws of Virginia and a Wholly Owned Subsidiary of Parent (“Purchaser”), and, solely for purposes of Article 1, Section 3.1, Section 5.1, Section 5.5(a), Section 5.5(e), Section 5.7(b), Section 5.7(c), Section 6.5(c), Article 8, Schedule A1 and Schedule A8 (the “Guaranteed Sections”), Altria Group, Inc., a corporation duly organized and existing under the Laws of Virginia (“Parent” and, together with the Company and Purchaser, the “Parties” and each, a “Party” (it being understood that, for the avoidance of doubt, Parent shall be a Party solely for such provisions)).
Indemnity AgreementIndemnity Agreement • March 2nd, 2020 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
This Indemnity Agreement (this “Agreement”) is made as of the [ ] day of [ ], 20[ ], between Cronos Group Inc., a body corporate incorporated under the laws of Ontario (the “Corporation”), and [ ] (the “Indemnified Party”), an individual resident in the [Province/State] of [●].
UNDERWRITING AGREEMENTUnderwriting Agreement • March 29th, 2018 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
GMP Securities L.P. (“GMP”) and BMO Nesbitt Burns Inc. (“BMO” and together with GMP, the “Lead Underwriters”), as co-lead underwriters, Cormark Securities Inc., Beacon Securities Limited and PI Financial Corp (together with the Lead Underwriters, the “Underwriters”) understand that Cronos Group Inc. (the “Corporation”) proposes to issue and sell 10,420,000 Common Shares (as hereinafter defined) (the “Firm Shares”). Upon and subject to the terms and conditions set forth below, the Underwriters hereby severally, but not jointly, agree to purchase from the Corporation, in the respective percentages provided for in Article 14 hereof, and by its acceptance hereof the Corporation agrees to sell to the Underwriters, at the Closing Time (as hereinafter defined), all but not less than all of the Firm Shares at a price of $9.60 per Firm Share (the “Offering Price”), for an aggregate purchase price of $100,032,000.
FORM OF CRONOS GROUP INC. RESTRICTED SHARE UNIT AGREEMENTRestricted Share Unit Agreement • August 6th, 2020 • Cronos Group Inc. • Medicinal chemicals & botanical products • Delaware
This Restricted Share Unit Award Agreement (hereinafter referred to as the “Agreement”) is made and entered into this ________ day of _______, 20__ (the “Grant Date”) by and between Cronos Group Inc. (hereinafter referred to as “Cronos”) and [●] (hereinafter referred to as the “Grantee”), pursuant to the Cronos Group Inc. 2020 Omnibus Equity Incentive Plan (hereinafter referred to as the “Plan”). All terms and provisions of the Plan are hereby incorporated into and shall govern the Agreement except where general provisions of the Plan are superseded by particular provisions of the Agreement. To the extent the Grantee is party to an employment agreement with the Company and any terms set forth herein conflict or are otherwise inconsistent with any terms or conditions set forth in Grantee’s employment agreement with the Company, the terms and conditions set forth in such employment agreement shall govern. All capitalized terms used in the Agreement shall have the same meaning given the t
EMPLOYMENT AGREEMENTEmployment Agreement • March 2nd, 2020 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
WHEREAS the Company and the Employee have agreed that the Employee shall be employed by the Company under the terms and conditions set out herein;
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT between GINKGO BIOWORKS, INC. and CRONOS GROUP INC.Collaboration and License Agreement • June 4th, 2021 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
THIS AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT, effective as of June 3, 2021 (the “Effective Date”), is entered into by and between Ginkgo Bioworks, Inc., a corporation duly organized and existing under the laws of the State of Delaware, U.S.A., having a place of business at 27 Drydock Ave, 8th Floor, Boston, Massachusetts 02210, U.S.A. (“Ginkgo”), and Cronos Group Inc., a corporation duly organized and existing under the laws of the Province of British Columbia, Canada, having a place of business at 111 Peter Street, Suite 300, Toronto, Ontario M5V 2H1, Canada (“Cronos”). Ginkgo and Cronos are sometimes also referred to herein each as a “Party” and together as the “Parties”.
WAIVER AND AMENDING AGREEMENTWaiver and Amending Agreement • February 29th, 2024 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
November 26, 2021 Xiuming Shum At the Address on file with the Company Dear Xiuming, This letter agreement (this “Letter Agreement”), effective as of the date hereof (the “Effective Date”), sets forth the terms and conditions of our agreement...Letter Agreement • November 30th, 2021 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among CRONOS GROUP INC., REDWOOD HOLDING GROUP, LLC and, solely for purposes of Article 4, Section 6.6, Section 6.7(a), Section 7.2(a)(ii), Section 7.2(c)(ii), Section 7.2(e)(ii), Section 9.2, Article 10...Membership Interest Purchase Agreement • August 2nd, 2019 • Cronos Group Inc. • Medicinal chemicals & botanical products • Delaware
This MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “Agreement”), dated as of August 1, 2019, is entered into by and among Cronos Group Inc., a corporation formed under the Business Corporations Act (Ontario) (“Buyer”), Redwood Holding Group, LLC, a Delaware limited liability company (“Seller”), and, solely for purposes of Article 4, Section 6.6, Section 6.7(a), Section 7.2(a)(ii), Section 7.2(c)(ii), Section 7.2(e)(ii), Section 9.2, Article 10 and Exhibit A, the Key Persons (together with Buyer and Seller, the “Parties” (it being understood that, for the avoidance of doubt, the Key Persons shall each be a Party solely for such provisions)). Exhibit A contains definitions of certain capitalized terms used in this Agreement.
CRONOS GROUP INC. RESTRICTED SHARE UNIT AGREEMENTRestricted Share Unit Agreement • March 2nd, 2020 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
This Restricted Share Unit Agreement (hereinafter referred to as the “Agreement”) is made and entered into this 5th day of September, 2019 (the “Grant Date”) by and between Cronos Group Inc. (hereinafter referred to as the “Company”) and Robert Rosenheck (hereinafter referred to as the “Participant”), pursuant to the Cronos Group Inc. Employment Inducement Award Plan #1 (hereinafter referred to as the “Plan”). All terms and provisions of the Plan are hereby incorporated into and shall govern the Agreement except where general provisions of the Plan are superseded by particular provisions of the Agreement. All capitalized terms used in the Agreement shall have the same meaning given the terms in the Plan.
FORM OF CRONOS GROUP INC. RESTRICTED SHARE UNIT AWARD AGREEMENT (Applicable for Israeli Grantees)Restricted Share Unit Award Agreement • August 6th, 2020 • Cronos Group Inc. • Medicinal chemicals & botanical products
This Restricted Share Unit Award Agreement (hereinafter referred to as the “Agreement”) is made and entered into this ________ day of _______, 20__ (the “Grant Date”) by and between Cronos Group Inc. (hereinafter referred to as “Cronos”) and [●] (hereinafter referred to as the “Grantee”), pursuant to the Cronos Group Inc. 2020 Omnibus Equity Incentive Plan (the “Plan”) and the Cronos Group Inc. Israeli Sub Plan (the “Sub-Plan” and, together with the Cronos Group Inc. 2020 Omnibus Equity Incentive Plan, the “Plans”). All terms and provisions of the Plan are hereby incorporated into and shall govern the Agreement except where general provisions of the Plan are superseded by particular provisions of the Agreement. All capitalized terms used in the Agreement shall have the same meaning given the terms in the Sub-Plan or, if not defined therein, the Plan. To the extent the Grantee is party to an employment agreement with the Company and any terms set forth herein conflict or are otherwise i
EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”)Executive Employment Agreement • May 10th, 2022 • Cronos Group Inc. • Medicinal chemicals & botanical products
WHEREAS the Company has engaged the services of the Executive in a senior and specialized capacity, and the Executive has extensive access to the customers, vendors, suppliers, distribution processes and other unique and valuable confidential information and trade secrets of the Company;
John Griese At the Address on file with the CompanyLetter Agreement • November 7th, 2022 • Cronos Group Inc. • Medicinal chemicals & botanical products • California
This letter agreement (this “Letter Agreement”), effective as of the date hereof (the “Effective Date”), sets forth the terms and conditions of our agreement regarding the separation of your employment with Cronos USA Client Services LLC, a limited liability company incorporated in the State of Delaware (“CCS”), and Hortican Inc., a corporation organized under the federal laws of Canada (“Hortican), wholly owned subsidiaries of Cronos Group Inc., a corporation organized under the laws of the Province of British Columbia (“Cronos Group”). Unless context otherwise requires, capitalized terms used in this Letter Agreement that are not defined herein have the meanings set forth in your Employment Agreement with the CCS, dated as of January 10, 2022 (the “Employment Agreement”). For the avoidance of doubt, this Letter Agreement supersedes our letter dated October 18, 2022 regarding your separation from the Company.
AMENDED AND RESTATED SUPPLY AGREEMENT between CRONOS GROWING COMPANY INC. and PEACE NATURALS PROJECT INC. dated as of JUNE 20, 2024Supply Agreement • June 25th, 2024 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
This Amended and Restated Supply Agreement, dated as of June 20, 2024 (this “Agreement”), is entered into between CRONOS GROWING COMPANY INC., a corporation incorporated under the federal laws of Canada (“Seller”), and PEACE NATURALS PROJECT INC., a corporation existing under the laws of Canada (“Buyer”, and together with Seller, the “Parties”, and each, a “Party”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 2nd, 2020 • Cronos Group Inc. • Medicinal chemicals & botanical products • California
This Executive Employment Agreement (this “Agreement”) is entered into by and between REDWOOD WELLNESS, LLC, a Delaware limited liability company (the “Company”), Robert Rosenheck (the “Executive”), and, solely for the purposes specified herein, CRONOS GROUP INC., a corporation organized under the laws of the Province of Ontario (“Cronos Group”).
Anna Shlimak At the Address on file with the Company Dear Anna,Letter Agreement • March 1st, 2022 • Cronos Group Inc. • Medicinal chemicals & botanical products
This letter agreement (this “Letter Agreement”), effective as of the date hereof (the “Effective Date”), sets forth the terms and conditions of our agreement regarding your position as Senior Vice President, Corporate Affairs. Capitalized terms used in this Letter Agreement that are not defined herein have the meanings set forth in your employment agreement with Cronos USA Client Services LLC, dated as of February 21, 2020 (the “Employment Agreement”).
EXECUTION VERSION AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTRestricted Share Unit Award Agreement • March 21st, 2022 • Cronos Group Inc. • Medicinal chemicals & botanical products • Delaware
WHEREAS a predecessor to Cronos Group and the Executive previously entered into an employment agreement, dated as of August 10, 2016, and as amended by the oral amendment effective in June 2019 (the “First Agreement”);
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 9th, 2023 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
WHEREAS the Company wishes to continue to engage the services of the Executive in a senior and specialized capacity and the Executive has extensive access to the customers, vendors, suppliers, distribution processes and other unique and valuable confidential information and trade secrets of the Company;
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 2nd, 2020 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
WHEREAS the Company wishes to engage the services of the Executive in a senior and specialized capacity and the Executive will have extensive access to the customers, vendors, suppliers, distribution processes and other unique and valuable confidential information and trade secrets of the Company;
Jeff Jacobson At the Address on file with the CompanyLetter Agreement • November 7th, 2022 • Cronos Group Inc. • Medicinal chemicals & botanical products
This letter agreement (this “Letter Agreement”), effective as of November 7, 2022 (the “Effective Date”), sets forth the terms and conditions of our agreement regarding your new position as Chief Growth Officer. Capitalized terms used in this Letter Agreement that are not defined herein have the meanings set forth in your employment agreement with Hortican Inc., a corporation organized under the federal laws of Canada (the “Company”), dated as of June 21, 2019 (the “Employment Agreement”).
AMENDING AGREEMENTAmending Agreement • February 29th, 2024 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 2nd, 2020 • Cronos Group Inc. • Medicinal chemicals & botanical products
This First Amendment to the Collaboration and License Agreement (this “First Amendment”) is entered into as of May 9, 2019 (the “First Amendment Effective Date”), by and between Ginkgo Bioworks, Inc., a corporation duly organized and existing under the laws of the State of Delaware, U.S.A., having a place of business at 27 Drydock Ave, 8th Floor, Boston, Massachusetts 02210, U.S.A. (“Ginkgo”), and Cronos Group Inc., a corporation duly organized and existing under the laws of the Province of Ontario, Canada, having a place of business at 720 King Street West, Suite 320, Toronto, Ontario M5V 2T3, Canada (“Cronos”). Ginkgo and Cronos may each be referred to herein individually as a “Party” and collectively as the “Parties.”
WHISTLER MEDICAL MARIJUANA CORPORATION AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENTShareholders’ Agreement • February 22nd, 2018 • Cronos Group Inc. • British Columbia
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”)Executive Employment Agreement • February 29th, 2024 • Cronos Group Inc. • Medicinal chemicals & botanical products • Delaware
WHEREAS the Executive previously entered into an employment agreement with Hortican, another wholly owned subsidiary of Cronos Group, on June 21, 2019 (the “Original Agreement”);
COLLABORATION AND LICENSE AGREEMENT between GINKGO BIOWORKS, INC. and CRONOS GROUP INC.Collaboration and License Agreement • September 4th, 2018 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
THIS COLLABORATION AND LICENSE AGREEMENT, effective as of September 1, 2018 (the “Effective Date”), is entered into by and between Ginkgo Bioworks, Inc., a corporation duly organized and existing under the laws of the State of Delaware, U.S.A., having a place of business at 27 Drydock Ave, 8th Floor, Boston, Massachusetts 02210, U.S.A. (“Ginkgo”), and Cronos Group Inc., a corporation duly organized and existing under the laws of the Province of Ontario, Canada, having a place of business at 720 King Street West, Suite 320, Toronto, Ontario M5V 2T3, Canada (“Cronos”). Ginkgo and Cronos are sometimes also referred to herein each as a “Party” and together as the “Parties”.
EXECUTION VERSION AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) BETWEEN: CRONOS ISRAEL G.S. CULTIVATION LTD. (No. 515790988) (the “Company”) - and - RAN GORELIK, Israeli ID number 56789472, an individual residing in the City...Executive Employment Agreement • April 3rd, 2024 • Cronos Group Inc. • Medicinal chemicals & botanical products
EXECUTION VERSION 4855-8885-6758 v.7 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of April 24, 2024, is entered into by and between Cronos Group Inc., a corporation organized under the Laws of the Province of British Columbia,...7 Voting Agreement • April 25th, 2024 • Cronos Group Inc. • Medicinal chemicals & botanical products • Ontario
EXECUTION VERSION February 8, 2023 Robert Madore At the Address on file with the Company Dear Bob, This letter agreement (this “Letter Agreement”), effective as of the date hereof (the “Effective Date”), sets forth the terms and conditions of our...Letter Agreement • February 13th, 2023 • Cronos Group Inc. • Medicinal chemicals & botanical products
CRONOS GROUP INC. EMPLOYMENT INDUCEMENT AWARD PLAN #1Cronos Group Inc. • March 2nd, 2020 • Medicinal chemicals & botanical products • Ontario
Jerry Barbato At the Address on file with the CompanyLetter Agreement • August 6th, 2021 • Cronos Group Inc. • Medicinal chemicals & botanical products • Delaware
This letter agreement (this “Letter Agreement”), effective as of August 9, 2021 (the “Effective Date”), sets forth the terms and conditions of our agreement regarding the separation of your employment with Hortican Inc., a corporation organized under the federal laws of Canada (the “Company”). Capitalized terms used in this Letter Agreement that are not defined herein have the meanings set forth in your employment agreement with the Company, dated as of April 2, 2019 (the “Employment Agreement”).
Anna Shlimak At the Address on file with the CompanyCronos Group Inc. • February 28th, 2023 • Medicinal chemicals & botanical products
Further to our recent discussions, this letter agreement (this “Letter Agreement”), effective as of the date hereof (the “Effective Date”), confirms the following amendment to your employment agreement with Cronos USA Client Services LLC, a limited liability company incorporated in the State of Delaware (the “Company”), and solely for the purposes specified therein, Cronos Group Inc., a corporation organized under the laws of the Province of British Columbia, dated as of February 21, 2020 (the “Employment Agreement”). Capitalized terms used in this Letter Agreement that are not defined herein have the meanings set forth in the Employment Agreement.
OPTION PURCHASE AGREEMENT BY AND AMONG PHARMACANN INC., A DELAWARE CORPORATION, CRONOS USA HOLDINGS INC., A DELAWARE CORPORATION and upon execution of a joinder hereto, SUCH ADDITIONAL PURCHASERS Dated as of June 14, 2021Option Purchase Agreement • June 15th, 2021 • Cronos Group Inc. • Medicinal chemicals & botanical products • Delaware
This OPTION PURCHASE AGREEMENT (this “Agreement”), dated as of June 14, 2021, is made by and among PharmaCann Inc., a Delaware corporation (the “Company”), any Person who, pursuant to the terms hereof, has executed a joinder to this Agreement, in the form attached as Exhibit A (each a “Joinder”), and Cronos USA Holdings Inc., a Delaware corporation (the “Initial Purchaser”, and, together with any Person who executes a Joinder pursuant to the terms hereof, a “Purchaser”, the Company and each Purchaser, each a “Party” and, collectively, the “Parties”).
